LLY Stock Recent News

Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.

Eli Lilly beat earnings expectations for the first quarter and raised its outlook for the year.

Lilly missed Wall Street's revenue estimate for the first quarter. However, the drugmaker easily beat the consensus Q1 earnings estimate.

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Eli Lilly (LLY) stock jumped in early trading Tuesday after the drugmaker reported first-quarter earnings that beat analysts' expectations and raised its guidance thanks to continued high demand for the company's weight-loss drugs.

Eli Lilly (LLY) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of $2.53 per share. This compares to earnings of $1.62 per share a year ago.

U.S. stock futures ticked lower in premarket trading on Tuesday as earnings reports from consumer giants continued to roll in and the Federal Reserve began its two-day policy meeting.

Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's weight loss drugs, growth outlook, and more.

Eli Lilly and Co (NYSE:LLY)'s weight loss medication Mounjaro drove impressive first-quarter earnings results for the US pharmaceuticals megacap. Mounjaro generated worldwide revenue of $1.81 billion in the three-month period, representing an increase from $568.5 million in the first quarter of 2023.

The pharmaceutical company reported adjusted earnings of $2.58 a share for the first quarter of 2024, up 59% from the same period a year earlier. Revenue rose 26% to $8.77 billion.